ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Announcement type
Time
13 announcements with these filters
JB Chemicals & Pharmaceuticals' amalgamation with Torrent Pharmaceuticals received NCLT sanction. The scheme will become effective upon filing with the Registrar of Companies.
Pradeep Kumar Singh and Suresh Bhise retired from the company. These changes in senior management are effective from June 30, 2026.
JB Chemicals clarified its audited financial results to the exchange. The board-approved results were signed by a director as authorized.
Mr. Bhushan Sachdev resigned as Executive Vice President – Supply Chain Management effective June 12, 2026. Investors should note the departure of a key supply chain executive.
JB Chemicals & Pharmaceuticals Limited filed its Business Responsibility and Sustainability Report for FY 2025-26. The report details company ESG performance, sustainability targets, and governance frameworks.
JB Chemicals & Pharmaceuticals filed its FY26 Business Responsibility and Sustainability Report. The filing highlights its ₹3889.89 Crore turnover and ESG progress for investor review.
JB Chemicals & Pharmaceuticals released its FY26 Integrated Annual Report, recording ₹4,148 Crore revenue. The company maintains strong growth momentum in domestic cardiology and international markets.
JB Chemicals & Pharmaceuticals announced its 50th AGM on June 17, 2026. Shareholders will consider a final dividend of ₹9.30 per share for the 2025-26 fiscal year.
J.B. Chemicals & Pharmaceuticals convened its 50th AGM for June 17, 2026. Shareholders will consider a final dividend of ₹9.30 per equity share.
JB Chemicals & Pharmaceuticals Ltd filed its Annual Secretarial Compliance Certificate for FY 2025-26. Practising Company Secretaries confirmed the company met all applicable SEBI regulatory requirements.
J.B. Chemicals & Pharmaceuticals fixed May 29, 2026, as the record date for final dividend eligibility. This determines which shareholders receive the 2025-26 payout.
Q4 FY26 marked an operational reset following Torrent Pharma's acquisition of a controlling stake. Management focused on integration, distribution optimization, and rationalizing low-margin trade generics.
Q4 FY26 shows operational reset post Torrent Pharma acquisition; revenue at ₹904cr (down 5% YoY) with adjusted EBITDA margin improving to 27%.